Showing results (41-50 of 119) with videos related to
Sort By:
Pageof 12
European Urology Oncology|August 15, 2019
Radium-223 Within the Evolving Treatment Options for Metastatic Castration-resistant Prostate Cancer: Recommendations from a European Expert Working GroupJoe M O'Sullivan, Joan Carles, Richard Cathomas, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 5, 2025
Efficacy, Safety, Blood Kinetics, and 213Bi Distribution Studies of [225Ac]Ac-SibuDAB in Prostate Cancer PatientsStefan Schmitl, Elisabeth Kretschmer-Chott, Eva-Maria Patronas, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 21, 2023
Antihormonal-Treatment Status Affects 68Ga-PSMA-HBED-CC PET Biodistribution in Patients with Prostate CancerKilian Kluge, David Haberl, Holger Einspieler, et al.Clinical Genitourinary Cancer|July 24, 2019
Prevalence and Prognostic Value of the Polymorphic Variant 1245A>C of HSD3B1 in Castration-resistant Prostate CancerJudith Stangl-Kremser, Ursula Lemberger, Melanie R Hassler, et al.The Prostate|January 13, 2004
Response to sublethal heat treatment of prostatic tumor cells and of prostatic tumor infiltrating T-cellsGero Kramer, Georg E Steiner, Marion Gröbl, et al.Cancers|April 3, 2021
Extracellular Vesicle-Associated Tissue Factor Activity in Prostate Cancer Patients with Disseminated Intravascular CoagulationLena Hell, Thomas Däullary, Vanessa Burghart, et al.European Journal of Nuclear Medicine and Molecular Imaging|May 1, 2024
Comparison of discovery rates and prognostic utility of [68Ga]Ga-PSMA-11 PET/CT and circulating tumor DNA in prostate cancer-a cross-sectional studyKilian Kluge, Holger Einspieler, David Haberl, et al.Cancer Research|March 5, 2004
Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18Gero Kramer, Hamdiye Erdal, Helena J M M Mertens, et al.European Journal of Nuclear Medicine and Molecular Imaging|November 30, 2019
Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeksSazan Rasul, Marcus Hacker, Elisabeth Kretschmer-Chott, et al.Wiener Klinische Wochenschrift|February 3, 2016
Austrian recommendations on Targeted Hormone Therapy for metastatic, castration-resistant prostate cancerAnton Ponholzer, Wolfgang Loidl, Jasmin Bektic, et al.Pageof 12